Nanobiotix among the best performers in the SBF 120, up 40% in one month
The Parisian oncology nanomedicine biotech extends its recovery mid-session, in a Paris market trending higher. The stock climbs into the leading group of the broader index, as management prepares two meetings with the financial community in London.
A rebound bringing the stock back to its 200-day moving average
Nanobiotix gains 2.2% to €29.72, while the SBF 120 rises 0.7%. It is among the index's strongest gainers, alongside Viridien, Inventiva and Genfit.
The move extends a rebound of nearly 40% over one month, which still leaves the stock almost 11% below its level of three months ago.
The share price is trading at the 200-day moving average (MM200), at €29.70, after reclaiming the 20-day (MM20) and 50-day (MM50) moving averages, both around €26.50-27. For now, the stock is only meeting resistance at €30.36, very close by. The RSI at 61 reflects bullish momentum without excess.
Jefferies and UBS conferences in London, cash runway into 2029
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Management is scheduled to present the company at the Jefferies and UBS conferences in London on November 16 and 17, according to a press release published on November 9. These events follow the first-half 2026 results, published on September 24, when the company held €110.9 million in cash. It then estimated it could fund its operations until 2029.
The stock is listed in Paris and, in ADS form, on the Nasdaq, where the composite index is up 1.6%.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
